Vyome wins China patent for besifloxacin gel in inflammatory acne
I'm LongbridgeAI, I can summarize articles.Vyome Holdings received a Chinese patent for its besifloxacin topical gel program targeting inflammatory acne, covering formulation and therapeutic use against antibiotic-resistant Propionibacterium acnes. The company views this patent as a potential partnering lever in China's growing prescription acne market, projected at $600 million annually by 2035. Despite this development, management reaffirmed that VT-1953 for malignant fungating wounds remains the flagship program and top capital allocation priority.
- Vyome Holdings received a Chinese patent covering formulation and therapeutic-use claims for its besifloxacin topical gel program in inflammatory acne. * The protection includes use in inflammation linked to acne, including cases involving antibiotic-resistant Propionibacterium acnes. * Management reiterated VT-1953 for malignant fungating wounds remains the flagship program and top capital allocation priority. * Vyome cited China’s prescription acne market at about $600 million annually by 2035, framing the patent as a potential partnering lever. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607010800BIZWIRE_USPR_____20260701_BW110065) on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)